Todos os posts

Estudo randomizado | Efeito da intervenção de trabalhadores da saúde da comunidade sobre uso do cuidado intensivo, planejamento de cuidado avançado e desfechos relatados pelo paciente entre adultos com câncer em estágios avançados.

4 Jul, 2022 | 11:53h

Effect of a Community Health Worker Intervention on Acute Care Use, Advance Care Planning, and Patient-Reported Outcomes Among Adults With Advanced Stages of Cancer: A Randomized Clinical Trial – JAMA Oncology (gratuito por tempo limitado)

Ver também: Visual Abstract

---

Estudo randomizado | Efeitos da estratégia perioperatória de “enhanced recovery” após esofagectomia minimamente invasiva.

4 Jul, 2022 | 11:51h

The effect of enhanced recovery after minimally invasive esophagectomy: a randomized controlled trial – Surgical Endoscopy

Conteúdos relacionados:

Guidelines for Perioperative Care in Esophagectomy: Enhanced Recovery After Surgery (ERAS^®) Society Recommendations – World Journal of Surgery

Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines

Top 100 Most-Cited Articles on Enhanced Recovery After Surgery: A Bibliometric Analysis and Visualized Study – Frontiers in Surgery

Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery: ERAS and Oesophagectomy – Annals of Surgical Oncology

Resumo visual: ASO Visual Abstract: Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery—ERAS and Esophagectomy

Enhanced recovery after surgery (ERAS) programs for esophagectomy – Journal of Thoracic Disease

---

Estudo randomizado | Injeção intra-articular conjugada de diclofenaco-hialuronato para osteoartrite de quadril, tornozelo, ombro e cotovelo.

4 Jul, 2022 | 11:45h

Diclofenac–hyaluronate conjugate (diclofenac etalhyaluronate) intra-articular injection for hip, ankle, shoulder, and elbow osteoarthritis: a randomized controlled trial – BMC Musculoskeletal Disorders

---

Estudo randomizado | Dieta FODMAP vs. medicação em pacientes de atenção primária com síndrome do intestino irritável.

4 Jul, 2022 | 11:44h

Diet or medication in primary care patients with IBS: the DOMINO study – a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute – Gut (link para o resumo – $ para o texto completo)

---

Análise agrupada de estudos clínicos placebo-controlados | Segurança da empagliflozina em pacientes com diabetes tipo 2 e doença renal crônica.

4 Jul, 2022 | 11:38h

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials – Diabetes Care

---

Revisão | Manejo nutricional para pacientes adultos críticos que requerem ventilação não invasiva.

4 Jul, 2022 | 11:33h

Nutrition Management for Critically Ill Adult Patients Requiring Non-Invasive Ventilation: A Scoping Review – Nutrients

---

Breve revisão | Ultrassonografia “point-of-care” para pacientes críticos.

4 Jul, 2022 | 11:32h

Point-of-care ultrasound for critically-ill patients: A mini-review of key diagnostic features and protocols – World Journal of Critical Care Medicine

---

Revisão | Infecção pelo vírus Lassa.

4 Jul, 2022 | 11:31h

Lassa Virus Infection: a Summary for Clinicians – International Journal of Infectious Diseases

---

Estudo randomizado | Efeito de apatinibe com doxorrubicina lipossomal peguilada vs. doxorrubicina lipossomal peguilada isoladamente sobre o câncer ovariano recidivante resistente à platina.

4 Jul, 2022 | 11:30h

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial – JAMA Oncology

Ver também: Visual Abstract

---

Estudo randomizado | Atezolizumabe com terapia neoadjuvante antirreceptor 2 do fator de crescimento epidérmico humano e quimioterapia no câncer de mama inicial positivo para receptor 2 do fator de crescimento epidérmico humano.

4 Jul, 2022 | 11:29h

Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial – Journal of Clinical Oncology

Comentário: Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer – OncLive

 

Comentário no Twitter

Presented at #ESMO VP6, IMpassion050 is now published on JCO. The addition of atezo to neoadjuvant ddAC-T+HP doesn’t increase pCR rates in HER2+ EBC, neither in ITT (left) nor PD-L1+ (right). Significant increase in toxicity with atezo, including 5 deaths.https://t.co/fL6mEjKTTS pic.twitter.com/2fYStkh8Zt

— Paolo Tarantino (@PTarantinoMD) June 28, 2022

 

---